

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL:

USAN	YTTRIUM Y 90 LABETUZUMAB TETRAJETAN
PRONUNCIATION	it' ree um la be too zoo' mab te trax' e tan
THERAPEUTIC CLAIM	radioimmunotherapy (RAIT) for CEA-expressing tumors in colorectal, pancreatic, lung, breast, ovarian, and medullary thyroid cancer
CHEMICAL NAMES	
	1) immunoglobulin G1, anti-(human carcinoembryonic antigen) (human-mouse monoclonal hMN-14 $\gamma$ -chain), disulfide with human-mouse monoclonal hMN-14 $\kappa$ -chain, dimer, 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid conjugate, yttrium-90Y chelate
	2) immunoglobulin G1 (human-mouse monoclonal hMN-14 $\gamma$ -chain anti-human carcinoembryonic antigen), disulfide with human-mouse monoclonal hMN-14 $\kappa$ -chain, dimer, 2,2',2'',2'''-(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetryl)tetraacetic acid conjugate, yttrium-90Y chelate
MOLECULAR WEIGHT	Approximately 150,000 Daltons
TRADEMARK	Unknown as yet
MANUFACTURER	Immunomedics, Inc.
CODE DESIGNATION	<sup>90</sup> Y-DOTA-hMN14
<u>CAS</u> REGISTRY NUMBER	501423-30-9